Corporate Banner
Satellite Banner
Technology Networks Header
Friday, July 25, 2014
Technology Networks
 
Register | Sign in
Home Page>News

  News Archive

Gene Study Shows How Sheep First Separated from Goats
Saturday, June 07, 2014
Findings support the development of DNA testing to speed-up selective breeding programmes.

JCVI Awarded 5 Year, Approximately $25 Million NIH Grant to Establish GCID
Saturday, June 07, 2014
Center will utilize next generation genomic sequencing and analysis technologies to better understand infectious disease pathogens, and create resource for the research community.

BD to Distribute AITbiotech Pte Ltd Assays in the Asia Pacific Region
Friday, June 06, 2014
The AITbiotech abTES™ BM qPCR assays are optimized on the BD MAX™ System.

Ventana, MedImmune to Develop a custom Assay Immunotherapy for Clinical Trials
Thursday, June 05, 2014
Companies are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma.

New Test Predicts If Breast Cancer Will Spread
Thursday, June 05, 2014
A test that counts the number of locations in tumor specimens where tumor cells may invade blood vessels predicted the risk of metastasis for the most common type of breast cancer.

Pivotal Phase III Data in PV Show that Ruxolitinib Achieved Superior Disease Control
Thursday, June 05, 2014
The trial met the primary composite endpoint of hematocrit control and at least a 35 percent reduction in spleen volume.

Thermo Fisher, Cellectis Enter TAL Nucleases Licensing Agreement
Thursday, June 05, 2014
Cellectis and Thermo Fisher Scientific announced that they have entered into a series of agreements covering the uses of TAL nucleases under the brand name TALEN™.

Merck’s Melanoma Drug Shows Overall Survival Rate of 69%
Wednesday, June 04, 2014
Pembrolizumab as monotherapy shows estimated overall survival rate at one year across 411 advanced melanoma patients with varying stages of disease and prior therapy.

Agalimmune Receives £1.2 million ($2 million) Milestone Payment
Wednesday, June 04, 2014
Agalimmune’s Alphaject technology, an injectable oncology therapy has completed a Phase I trial in melanoma. Data presented at AACR and ASCO.

<< 9 10 11 12 13 14 15 >>
Showing Results 111 - 120 of 8911
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv